Is high performance computing a requirement for novel drug discovery and how will this impact academic efforts?
Savíns Puertas‐Martín(University of Almería), Horacio Pérez‐Sánchez(Universidad Católica de Murcia), Juana L. Redondo(University of Almería), Pilar M. Ortigosa(University of Almería), María Paredes-Ramos(Universidade da Coruña), Ol’ha O. Brovarets’(National Academy of Sciences of Ukraine), Antonio Jesús Banegas‐Luna(Universidad Católica de Murcia)
Cited by 33
Related Papers
MCC950 closes the active conformation of NLRP3 to an inactive state
|Nature Chemical Biology|2019|446
Neural network and deep-learning algorithms used in QSAR studies: merits and drawbacks
|Drug Discovery Today|2018|224
A Comprehensive Docking and MM/GBSA Rescoring Study of Ligand Recognition upon Binding Antithrombin
|Current Topics in Medicinal Chemistry|2017|193
High-Throughput parallel blind Virtual Screening using BINDSURF
|BMC Bioinformatics|2012|190
Managing, Analysing, and Integrating Big Data in Medical Bioinformatics: Open Problems and Future Perspectives
|BioMed Research International|2014|175